The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

GSK plc and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, announced that they have entered ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

Bayer and GSK have a Zacks Rank #2 (Buy) each, while Novo Nordisk, AbbVie, and Merck carry a Zacks Rank of 3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GSK has announced that it will be acquiring Boston Pharmaceuticals’ phase 3-ready liver disease candidate in a deal worth up to $2bn. Efimosfermin alfa is an investigational drug in clinical ...

GSK is paying $1.2 billion upfront to Boston Pharmaceuticals for an experimental drug to treat MASH. Eli Lilly plans to expand Purdue University collaboration with up to a $250 million investment ...

Just yesterday, GSK disclosed it was acquiring Boston Pharmaceuticals’ FGF21 analogue efimosfermin for $2bn, with plans to combine it with its in-house siRNA candidate GSK’990 to address more ...